Remaining shareholders who did not tender should promptly submit their shares to receive the $124.00 per share merger consideration. The stock will be delisted and deregistered, eliminating any further public trading. No remaining catalyst for the common equity.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK AT ENTRY AT T+5- T+0 · Jul 15 $123.96entry
- T+1 · 4mo ago 0.00%α +0.54% · $123.96
- T+5 · 4mo ago 0.00%α +0.98% · $123.96
- T+20 · due 3mo ago Pending
- T+60 · due 6w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK plc has completed its acquisition of Nuvalent, Inc. via a tender offer and merger. The tender offer expired with 91.3% of shares tendered, and the merger closed on July 15, 2026, at $124.00 per share in cash, representing a total equity value of approximately $10.6 billion. All outstanding shares, options, and RSUs were cashed out, and the company will be delisted from Nasdaq.
Key Facts
- Tender offer expired on July 14, 2026 with 72,518,967 shares (91.3% of outstanding) validly tendered
- Merger closed on July 15, 2026 under DGCL Section 251(h) without a stockholder vote
- Shareholders received $124.00 per share in cash, less applicable withholding
- Total equity value of the transaction approximately $10.6 billion
- All outstanding stock options and RSUs were cancelled and converted to cash at the Offer Price
- Nasdaq trading halted after market close on July 14, 2026; delisting and deregistration initiated
- All incumbent directors and officers resigned; replaced by appointees of GSK's acquisition subsidiary
- Certificate of incorporation and bylaws were amended and restated
Financial Impact
Transaction valued at approximately $10.6 billion in total equity value, with all outstanding shares converted to $124.00 cash per share. No ongoing public equity or financial reporting.
Risk Factors
- Shareholders who do not tender or demand appraisal rights may face delays in receiving cash
- Delisting and deregistration eliminate liquidity and public market access
- Potential appraisal litigation if shareholders believe the price was inadequate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-304126 |
| Document: d52896d8k.htm | 0001193125-26-304126 |
| Document: d52896dex31.htm | 0001193125-26-304126 |
| Document: 0001193125-26-304126-index-headers.html | 0001193125-26-304126 |
| Document: 0001193125-26-304126-index.html | 0001193125-26-304126 |
| Document: 0001193125-26-304126.txt | 0001193125-26-304126 |
Track record
18 reports on NUVL
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +21.01% at T+60 after the Apr 7, 2026 report. 4 of 7 went positive at some point.
Filters
- Jul 27, 202616w ago 15-12G Neutral 3/10 No price data
- Jul 15, 202617w ago 25-NSE Neutral 3/10 Entry $123.96 No price data
- Jul 15, 202617w ago 8-K Bullish 5/10 Viewing Entry $123.96 No price data
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $123.80 No price data
- Jul 6, 202619w ago Insider Cluster Neutral 3/10 Entry $123.72 No price data
- Jun 11, 202622w ago Insider Cluster Neutral 2/10 Entry $123.25 to $123.90 ▲ +0.53% −1.25% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $123.45 to $123.83 ▲ +0.31% −1.58% vs SPY
- Jun 9, 202622w ago 8-K Bullish 8/10 Entry $123.25 to $123.77 ▲ +0.42% −1.02% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $102.40 to $90.18 ▼ −11.93% −15.07% vs SPY
- Apr 29, 202628w ago Insider Cluster Neutral 2/10 Entry $99.10 to $107.38 ▲ +8.36% +2.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers